Francis Patrick Ostronic - Oct 20, 2023 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Role: Director
Signature: /s/ Francis Patrick Ostronic
Stock symbol: CYTH
Transactions as of: Oct 20, 2023
Transactions value $: $35,030
Form type: 4
Date filed: 10/23/2023, 06:07 AM
Previous filing: Aug 22, 2023
Next filing: Nov 30, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYTH	Common Stock	Exercise of in-the-money or at-the-money derivative security	$42.5K	+59.9K	+24.04%	$0.71	309K	Oct 20, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYTH	Warrant to Purchase Common Stock	Exercise of in-the-money or at-the-money derivative security	-$7.49K	-59.9K	-100%	$0.13	0	Oct 20, 2023	Common Stock	59.9K	$0.71	Direct
transaction	CYTH	Warrant to Purchase Common Stock	Purchase		+65.9K			65.9K	Oct 20, 2023	Common Stock	65.9K	$0.95	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 59,881 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.

Content

The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 59,881 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.